Literature DB >> 24114682

Short-term but not long-term loss of patency of venous reconstruction during pancreatic resection is associated with decreased survival.

Irmina Gawlas1, Irene Epelboym, Megan Winner, Joseph DiNorcia, Yanghee Woo, James L Lee, Beth A Schrope, John A Chabot, John D Allendorf.   

Abstract

BACKGROUND: Pancreatic surgery with vascular reconstruction is increasingly performed to offer the benefits of surgical resection to patients with locally advanced disease. The short- and long-term patency rates and the clinical significance of thrombosis of such reconstructions are unknown.
METHODS: We reviewed pancreatectomies requiring venous reconstruction from 1994 to 2011. We sought to identify predictors of acute (within 30 days) and late thrombosis. We compared survival of patients with thrombosis to patients with patent reconstructions.
RESULTS: Of 203 pancreatectomies requiring venous reconstruction, acute thrombosis occurred in nine (4.4 %) cases and was associated with increased perioperative mortality (22.2 versus 4.6 %, p = 0.023). Even when nonfatal, acute thrombosis was associated with decreased median survival (7.1 versus 15.9 months, p = 0.011) and increased hazard of death (hazard ratio 8.6, confidence interval 3.7-19.9, p < 0.001). A late loss of patency was seen in 31.2 % of cases at a median of 9.5 months. Later loss of patency was not associated with decreased median survival or increased hazard of death.
CONCLUSIONS: Acute thrombosis of the portal venous reconstructions after pancreatectomy is associated with increased perioperative mortality and, even when nonfatal, is associated with decreased survival. Late loss of patency occurs in one-third of patients but does not affect survival.

Entities:  

Mesh:

Year:  2013        PMID: 24114682     DOI: 10.1007/s11605-013-2375-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  8 in total

1.  Durability of portal venous reconstruction following resection during pancreaticoduodenectomy.

Authors:  Rory L Smoot; John D Christein; Michael B Farnell
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

2.  Targeting early deaths following pancreaticoduodenectomy to improve survival.

Authors:  Whalen Clark; Melissa Silva; Natalie Donn; Kenneth Luberice; Leigh Ann Humphries; Harold Paul; Jonathan Hernandez; Sharona B Ross; Alexander Rosemurgy
Journal:  J Gastrointest Surg       Date:  2012-08-09       Impact factor: 3.452

3.  Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques.

Authors:  Matthew H G Katz; Jeffrey E Lee; Peter W T Pisters; Roman Skoracki; Eric Tamm; Jason B Fleming
Journal:  J Am Coll Surg       Date:  2012-08       Impact factor: 6.113

4.  The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database.

Authors:  Anthony W Castleberry; Rebekah R White; Sebastian G De La Fuente; Bryan M Clary; Dan G Blazer; Richard L McCann; Theodore N Pappas; Douglas S Tyler; John E Scarborough
Journal:  Ann Surg Oncol       Date:  2012-08-30       Impact factor: 5.344

5.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

6.  Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis.

Authors:  Ryan P Merkow; Karl Y Bilimoria; Martin D McCarter; Mark E Cohen; Carlton C Barnett; Mehul V Raval; Joseph A Caprini; Howard S Gordon; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2011-07       Impact factor: 12.969

7.  Resection of portovenous structures to obtain microscopically negative margins during pancreaticoduodenectomy for pancreatic adenocarcinoma is worthwhile.

Authors:  Paul Toomey; Jonathan Hernandez; Connor Morton; Lorent Duce; Thomas Farrior; Desiree Villadolid; Sharona Ross; Alexander Rosemurgy
Journal:  Am Surg       Date:  2009-09       Impact factor: 0.688

8.  Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.

Authors:  John D Allendorf; Margaret Lauerman; Aliye Bill; Mary DiGiorgi; Nicole Goetz; Efsevia Vakiani; Helen Remotti; Beth Schrope; William Sherman; Michael Hall; Robert L Fine; John A Chabot
Journal:  J Gastrointest Surg       Date:  2007-09-05       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.